Nucleic Acid News and Research

RSS

Trovagene receives European patent titled, ‘Methods for Detection of Nucleic Acid Sequences in Urine’

Trovagene, Inc., a developer of trans-renal molecular diagnostics, announced it has received notice of issuance of European Patent No. 2216416 entitled "Methods for Detection of Nucleic Acid Sequences in Urine."

11 May 2012

Human iPS cells accrue genetic changes at about the same rate as replicating cells

A team of researchers from Johns Hopkins University and the National Human Genome Research Institute has evaluated the whole genomic sequence of stem cells derived from human bone marrow cells—so-called induced pluripotent stem (iPS) cells—and found that relatively few genetic changes occur during stem cell conversion by an improved method.

30 Apr 2012

Non-coding RNA gives off biological signals during viral infection

Once considered unimportant "junk DNA," scientists have learned that non-coding RNA (ncRNA) - RNA molecules that do not translate into proteins - play a crucial role in cellular function. Mutations in ncRNA are associated with a number of conditions, such as cancer, autism, and Alzheimer's disease.

25 Apr 2012

Ahram Biosystems launches cost-effective, high-performance portable PCR system

Ahram Biosystems, Inc., a leading innovator of new life science tools, today announced the launch of Palm PCR F1-12, the economy model of its innovative portable PCR system. The F1-12 system is a cost-effective, high-performance portable PCR system, delivering PCR amplification with high speed and sensitivity in a fully portable format.

23 Apr 2012

APS honors MCW professor with Henry Pickering Bowditch Lecture Award

High blood pressure, or hypertension, is a major problem worldwide, with the latest estimates suggesting that a billion people across the globe may have this condition. Hypertension not only takes an enormous cost on health and wellbeing, but it also exacts an expensive financial toll. Complications from this condition including kidney disease, and its resulting treatments, such as long-term dialysis and kidney transplant, are some of the costliest conditions the American health care system must contend with.

23 Apr 2012

FDA grants 510(k) clearance for QIAGEN’s molecular detection PCR technology

QIAGEN N.V. today announced that the U.S. Food and Drug Administration (FDA) has granted two 510(k) clearances for its real-time PCR (polymerase chain reaction) instrument Rotor-Gene Q MDx and a compatible test for the detection of Influenza A/B, the artus Infl A/B RG RT-PCR Kit, for in vitro diagnostic use.

From QIAGEN Manchester Limited 17 Apr 2012

Quest Diagnostics receives FDA clearance for Simplexa C. difficile Universal Direct test

Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to its Simplexa C. difficile Universal Direct Test on the 3M Integrated Cycler.

From Quest Diagnostics 12 Apr 2012

Bio-Path 2011 net loss increases to $2,363,344

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the year ended December 31, 2011.

4 Apr 2012

MO BIO introduces PowerMicrobiome RNA Isolation Kit

MO BIO Laboratories, Inc., the leader in soil, water and microbial nucleic acid purification, announces the launch of the PowerMicrobiome RNA Isolation Kit, the first kit available that is optimized for stool and gut material and provides high quality RNA for use in characterizing the human microbiome.

29 Mar 2012

DNA Electronics licenses technology platform for rapid, lab-free DNA detection to geneOnyx

DNA Electronics Ltd. a developer of semiconductor solutions for real-time DNA and RNA detection, today announces that it has licensed its ground-breaking Genalysis technology platform for rapid, lab-free DNA detection to geneOnyx, a company that is delivering on-the-spot genetic analytics services for cosmetics and skincare applications.

19 Mar 2012

Enzo Biochem to unveil data on AmpiProbe HCV assay at ESCMID meeting

Enzo Biochem Inc. announced today that the company will present for the first time peer-reviewed data on detection of hepatitis C virus (HCV) using its novel AmpiProbe technology platform, which provides low cost and high sensitivity real-time nucleic acid amplification assays.

9 Mar 2012

Biotech company defends patent on gene mutation for breast cancer

A US biotechnology company is defending the granting of a controversial patent over a common genetic mutation for breast cancer, rejecting accusations it amounts to the privatization of the human body.

21 Feb 2012

Scientists discover new mechanisms by which RNA drugs can control gene activity

Small RNA-based nucleic acid drugs represent a promising new class of therapeutic agents for silencing abnormal or overactive disease-causing genes, and researchers have discovered new mechanisms by which RNA drugs can control gene activity.

3 Feb 2012

Lab21 acquires new real time PCR technology

Lab21 Limited, the global specialist in personalized medicine and clinical diagnostics, today announces the completion of a worldwide license from Cooperative Diagnostics to use its suite of patents and expertise for the development of its growing pipeline of molecular diagnostic kits. Financial details of the agreement were not disclosed.

23 Jan 2012

Cryo-electron microscopy can visualize structures within viruses

Since the discovery of the microscope, scientists have tried to visualize smaller and smaller structures to provide insights into the inner workings of human cells, bacteria and viruses. Now, researchers at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health, have developed a new way to see structures within viruses that were not clearly seen before.

13 Jan 2012

New NIST clinical SRM can help in accurate CMV detection and treatment

A new clinical Standard Reference Material (SRM) from the National Institute of Standards and Technology (NIST) will help health care professionals more accurately diagnose and treat cytomegalovirus (CMV), a common pathogen that is particularly dangerous for infants and persons with weakened immune systems.

12 Jan 2012

miRagen, Silence partner to assess delivery potential of novel miRNA-based therapeutics

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, announces that it has signed an agreement with miRagen Therapeutics, Inc., to assess the delivery potential of Silence's proprietary DBTC delivery system with miRagen's novel microRNA-based therapeutics.

9 Jan 2012